/logo-16545883420.png){kind=logo}
Media Information
-
2021.01.06
Beijing Shenogen Pharma Group Ltd. Disclosed the New Findings Related to Icaritin treatment induced Immunomodulation in HCC Tumor Microenvironment
Recently, the internationally renowned European Journal of Immunology published …+Read More -
2020.09.25
Cancer Science Online Publication: Phase II Data Demonstrated Clinical Safety and Efficacy of First-in-Class Small Molecule Icaritin in Patients with Advanced HBV-related Hepatocellular Carcinoma
Congratulations to team investigators and ShenogenPharma teams. Cancer Science…+Read More -
2019.08.30
European Journal of Immunology (published online) New Evidence for Icaritin, a Small Molecule Discovered from a Chinese Herb by Beijing Shenogen Pharma Group, to Elicit Immunological Responses and Inhibit Tumor Growth
Recently, the renowned European Journal of Immunology published an article tit…+Read More -
2019.04.12
icaritin phase IIA trial showed favorable safety profiles and preliminary durable survival benefits in advanced HCC patients in BMC Cancer online Publication
Icaritin early phase Trial: With poor prognosis and limitedtreatment options for…+Read More -
2018.05.25
IDG-Backed Shenogen Said to Interview Banks for $300 Million IPO – Bloomberg
+Read More -
2018.03.26
Reward and risk: the two faces of Hong Kong’s new listing rules for biotech firms
Reward and risk: the two faces of HongKong’s new listing rules for biotech firm…+Read More